Critical Stepwise Decline of Antibodies against SARS-CoV-2 among Chronic Hemodialysis Patients 180 Days Post Comirnaty Vaccine

Nomy Levin-Iaina; Avital Angel-Korman; Adi Leiba; Esther Peres; Gabriel Bryk; Vladimir Rapoport; Zeev Katzir; Yoram Yagil; Tal Brosh-Nissimov

Critical Stepwise Decline of Antibodies against SARS-CoV-2 among Chronic Hemodialysis Patients 180 Days Post Comirnaty Vaccine

Nomy Levin-Iaina, Avital Angel-Korman, Adi Leiba, Esther Peres, Gabriel Bryk, Vladimir Rapoport, Zeev Katzir, Yoram Yagil, Tal Brosh-Nissimov

Research output: Contribution to journal › Article › peer-review

Abstract

Background: The reduced immune response of maintenance hemodialysis patients to coronavirus disease 2019 (COVID-19) vaccines is a major concern. Objectives: To analyze the late (6 months after full vaccination) antibody response and compare it to early post-vaccination titer. Methods: We conducted a multicenter prospective study of 13 hemodialysis units in Israel. Results: We demonstrated that the low titers observed among ESRD patients 2-3 months after vaccination with the Comirnaty vaccine (median 63.8 AU/ml) declined to critically lower values 6 months after full vaccination. (Median anti-S antibodies, 31 AU/ml). Seropositivity significantly declined among hemodialysis patients from 89% to 74% (P < 0.0001), although it did not significantly change among controls. Conclusions: We recommend all patients on hemodialysis receive a booster COVID-19 vaccine 6 months after the second dose.

Original language	English
Pages (from-to)	317-319
Number of pages	3
Journal	Israel Medical Association Journal
Volume	24
Issue number	5
State	Published - 1 May 2022
Externally published	Yes

Keywords

Comirnaty vaccine
anti-S antibodies
coronavirus disease 2019 (COVID-19)
hemodialysis
humoral response

ASJC Scopus subject areas

Medicine (all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{121a3c2954d8467faa97cf4447fbd51b,

title = "Critical Stepwise Decline of Antibodies against SARS-CoV-2 among Chronic Hemodialysis Patients 180 Days Post Comirnaty Vaccine",

abstract = "Background: The reduced immune response of maintenance hemodialysis patients to coronavirus disease 2019 (COVID-19) vaccines is a major concern. Objectives: To analyze the late (6 months after full vaccination) antibody response and compare it to early post-vaccination titer. Methods: We conducted a multicenter prospective study of 13 hemodialysis units in Israel. Results: We demonstrated that the low titers observed among ESRD patients 2-3 months after vaccination with the Comirnaty vaccine (median 63.8 AU/ml) declined to critically lower values 6 months after full vaccination. (Median anti-S antibodies, 31 AU/ml). Seropositivity significantly declined among hemodialysis patients from 89% to 74% (P < 0.0001), although it did not significantly change among controls. Conclusions: We recommend all patients on hemodialysis receive a booster COVID-19 vaccine 6 months after the second dose.",

keywords = "Comirnaty vaccine, anti-S antibodies, coronavirus disease 2019 (COVID-19), hemodialysis, humoral response",

author = "Nomy Levin-Iaina and Avital Angel-Korman and Adi Leiba and Esther Peres and Gabriel Bryk and Vladimir Rapoport and Zeev Katzir and Yoram Yagil and Tal Brosh-Nissimov",

year = "2022",

month = may,

day = "1",

language = "English",

volume = "24",

pages = "317--319",

journal = "Israel Medical Association Journal",

issn = "1565-1088",

publisher = "Israel Medical Association",

number = "5",

}

Critical Stepwise Decline of Antibodies against SARS-CoV-2 among Chronic Hemodialysis Patients 180 Days Post Comirnaty Vaccine. / Levin-Iaina, Nomy; Angel-Korman, Avital; Leiba, Adi; Peres, Esther; Bryk, Gabriel; Rapoport, Vladimir; Katzir, Zeev; Yagil, Yoram; Brosh-Nissimov, Tal.

In: Israel Medical Association Journal, Vol. 24, No. 5, 01.05.2022, p. 317-319.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Critical Stepwise Decline of Antibodies against SARS-CoV-2 among Chronic Hemodialysis Patients 180 Days Post Comirnaty Vaccine

AU - Levin-Iaina, Nomy

AU - Angel-Korman, Avital

AU - Leiba, Adi

AU - Peres, Esther

AU - Bryk, Gabriel

AU - Rapoport, Vladimir

AU - Katzir, Zeev

AU - Yagil, Yoram

AU - Brosh-Nissimov, Tal

PY - 2022/5/1

Y1 - 2022/5/1

N2 - Background: The reduced immune response of maintenance hemodialysis patients to coronavirus disease 2019 (COVID-19) vaccines is a major concern. Objectives: To analyze the late (6 months after full vaccination) antibody response and compare it to early post-vaccination titer. Methods: We conducted a multicenter prospective study of 13 hemodialysis units in Israel. Results: We demonstrated that the low titers observed among ESRD patients 2-3 months after vaccination with the Comirnaty vaccine (median 63.8 AU/ml) declined to critically lower values 6 months after full vaccination. (Median anti-S antibodies, 31 AU/ml). Seropositivity significantly declined among hemodialysis patients from 89% to 74% (P < 0.0001), although it did not significantly change among controls. Conclusions: We recommend all patients on hemodialysis receive a booster COVID-19 vaccine 6 months after the second dose.

AB - Background: The reduced immune response of maintenance hemodialysis patients to coronavirus disease 2019 (COVID-19) vaccines is a major concern. Objectives: To analyze the late (6 months after full vaccination) antibody response and compare it to early post-vaccination titer. Methods: We conducted a multicenter prospective study of 13 hemodialysis units in Israel. Results: We demonstrated that the low titers observed among ESRD patients 2-3 months after vaccination with the Comirnaty vaccine (median 63.8 AU/ml) declined to critically lower values 6 months after full vaccination. (Median anti-S antibodies, 31 AU/ml). Seropositivity significantly declined among hemodialysis patients from 89% to 74% (P < 0.0001), although it did not significantly change among controls. Conclusions: We recommend all patients on hemodialysis receive a booster COVID-19 vaccine 6 months after the second dose.

KW - Comirnaty vaccine

KW - anti-S antibodies

KW - coronavirus disease 2019 (COVID-19)

KW - hemodialysis

KW - humoral response

UR - http://www.scopus.com/inward/record.url?scp=85130862486&partnerID=8YFLogxK

M3 - Article

C2 - 35598056

AN - SCOPUS:85130862486

VL - 24

SP - 317

EP - 319

JO - Israel Medical Association Journal

JF - Israel Medical Association Journal

SN - 1565-1088

IS - 5

ER -

Critical Stepwise Decline of Antibodies against SARS-CoV-2 among Chronic Hemodialysis Patients 180 Days Post Comirnaty Vaccine

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this